Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Trastuzumab without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients: Randomized Controlled Trial

Next Previous
Trial Profile

Evaluation of Trastuzumab without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients: Randomized Controlled Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Methotrexate; Paclitaxel
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms RESPECT

Most Recent Events

  • 27 May 2025 According to the REVEAL GENOMICS Media Release, company announced the presentation of data from this study at the 2025 ASCO Annual Meeting.
  • 01 Mar 2022 Results of an analysis assessing the the cost-effectiveness of HER2-targeted trastuzumab plus chemotherapy in Japan, comparing it with trastuzumab monotherapy, published in the Clinical Drug Investigation
  • 01 Aug 2021 Results (n=57) assessing postoperative adjuvant trastuzumab plus chemotherapy negatively affected cognitive functioning during the post-chemotherapy period compared with trastuzumab monotherapy in older patients with HER2-positive breast cancer published in the Breast Cancer Research and Treatment

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top